Improving Office Based Treatment of Opioid Use Disorder With Technology

Status unconfirmed · Not applicable

Conditions studied: Opioid-use Disorder

In brief

The goal of this study is to evaluate whether using a novel drug-device combination to deliver buprenorphine/naloxone (B/N) to patients in office-based treatment for Opioid Use Disorder (OUD) is an effective way to improve compliance and treatment outcomes. The system introduces psychological and behavioral supports in addition to securing the medication between doses.

Key facts

Study ID

NCT03586466

Run by

MedicaSafe, Inc.

People needed

80

Starts

2018-12-01

Expected to finish

2020-09-01

Last updated by the study team

2019-07-19

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Be between the ages of 18 and 65 years old
• Be able to provide informed consent
• Be English-speaking
• Have consistent phone and/or internet access
• Deemed by physician as medically, psychiatrically, and otherwise appropriate for buprenorphine therapy
• Maintained on a stable B/N dose

You may not qualify if…

• Be younger than 18 or older than 65 years of age
• Chronic pain
• Be non-English speaking
• Be unable to complete informed consent
• Be pregnant

Where it is running

• Friends Research Institute — Baltimore, Maryland, United States (enrolling)
• Artemis Institute for Clinical Research — San Diego, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.